Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date

Por Pellesi, Lanfranco, Guerzoni, Simona, Pini, Luigi Alberto
Publicado no Clin Pharmacol Drug Dev (2017)

Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment

Por Guerzoni, Simona, Pellesi, Lanfranco, Baraldi, Carlo, Pini, Luigi Alberto
Publicado no J Headache Pain (2016)

Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal

Por Baraldi, Carlo, Pellesi, Lanfranco, Guerzoni, Simona, Cainazzo, Maria Michela, Pini, Luigi Alberto
Publicado no J Headache Pain (2017)

Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy

Por Guerzoni, Simona, Pellesi, Lanfranco, Baraldi, Carlo, Cainazzo, Michela Maria, Negro, Andrea, Martelletti, Paolo, Pini, Luigi Alberto
Publicado no Front Neurol (2017)

Triptans and CGRP blockade – impact on the cranial vasculature

Por Benemei, Silvia, Cortese, Francesca, Labastida-Ramírez, Alejandro, Marchese, Francesca, Pellesi, Lanfranco, Romoli, Michele, Vollesen, Anne Luise, Lampl, Christian, Ashina, Messoud
Publicado no J Headache Pain (2017)